Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?
Gaurav Goel Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Abstract: Colorectal cancer (CRC) is a major public health problem in the United States with an estimated 50,260 deaths in 2017. Over the past two decades, several agents have been approved...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-03-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/evolution-of-regorafenib-from-bench-to-bedside-in-colorectal-cancer-is-peer-reviewed-article-CMAR |